NEW YORK, May 23 /PRNewswire/ -- NexGenix Pharmaceuticals, a privately held biotechnology company focused on developing drugs to treat the orphan- designated tumor suppressor disorder, Neurofibromatosis, announced today that Allan E. Rubenstein, M.D., Chief Executive Officer of NexGenix, will present an overview of the company's drug development efforts at BIO VentureForum East 2006 on June 12-14, 2006. BIO Venture Forum East is a major showcase for emerging companies in the life sciences.
NexGenix will additionally present scientific findings at two key Neurofibromatosis meetings this year. Marco Giovannini, M.D., Ph.D., NexGenix's Chief Scientific Officer, will present data at the 2006 NF Scientific Consortium Meeting hosted in Aspen, CO June 4-6, by the Children's Tumor Foundation, and at the International Workshop on Neurofibromatosis Type 2 hosted in Paris, September 7-9, 2006 by Inserm (Institut national de la sante et de la recherche medicale). Dr. Ruihong Chen, VP for Research and Dr. Rubenstein will also present data on drug development for NF2 at the Inserm meeting.
About NexGenix Pharmaceuticals
NexGenix Pharmaceuticals is a US-based biotechnology company focused on drug development for Neurofibromatosis Types 1 and 2. Neurofibromatosis, or NF, is a genetic disorder characterized by the development of tumors along nerves. These slow growing tumors are resistant to radiation and chemotherapy and the only current treatment is repeated surgical removal. NexGenix has assembled a team of top NF clinicians and researchers on its Scientific Advisory Board and has developed a proprietary screening platform for both Neurofibromatosis Type 1 and 2. NexGenix will soon seek an IND for a unique treatment for NF1. A targeted treatment for NF2 is in early stage development.
For more information, please visit the NexGenix website at www.nexgenixpharm.com
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements.
Nexgenix PharmaceuticalsCONTACT: Michelle Morin, Corporate Development of NexgenixPharmaceuticals, +1-212-742-0210, mmorin@nexgenixpharm.com
Web site: http://www.nexgenixpharm.com/
